Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07236541

Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study

Chronic obstructive pulmonary disease (COPD) is frequently accompanied by airway mucus plugs, which are closely associated with airflow obstruction, acute exacerbations, and increased mortality. However, whether mucus plugs contribute to secondary pulmonary fibrosis remains unclear. This single-center, prospective, case-control study aims to investigate the relationship between airway mucus plugs and lung fibrosis in patients with COPD undergoing lung cancer surgery.

During surgery, distal non-tumorous lung tissues and airway mucus will be collected for histological and molecular analyses. Mucus plug burden will be quantified using AB-PAS staining, and fibrosis will be assessed using Masson staining. Expression of epithelial-mesenchymal transition (EMT) markers, fibrotic markers, and the mechanosensitive ion channel Piezo1 will also be measured. COPD patients (FEV₁/FVC <0.70) will be compared with non-COPD surgical controls.

The study aims to clarify whether mucus plugs are associated with increased fibrosis and to explore the potential involvement of mechanical-signaling pathways, including Piezo1 activation. Findings may provide new clinical and pathological evidence for mucus-induced fibrotic remodeling in COPD and help identify novel therapeutic targets.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ① Age ≥ 18 years old;
  • Planned radical resection for lung cancer, with postoperative pathological diagnosis of primary lung cancer;
  • During surgery, non tumor lung tissue at a distance of ≥ 5 cm from the tumor edge can be obtained; ④ Case group: Preoperative pulmonary function examination confirmed diagnosis of COPD (FEV ₁/FVC<0.70); ⑤ Control group: Preoperative lung function was normal (FEV ₁/FVC ≥ 0.70), with no history of COPD; ⑥ The subjects are able to understand and sign the informed consent form

Exclusion criteria

  • ① Clear presence of other interstitial lung diseases (ILD) or idiopathic pulmonary fibrosis before or during surgery (IPF)、 Fibrosis after pneumoconiosis or tuberculosis;
  • Active pulmonary infections (such as bacterial pneumonia, fungal infections, active tuberculosis);
  • Having received neoadjuvant radiotherapy or chemotherapy, which may affect the morphology or molecular results of distal lung tissue; ④ Combined severe immunodeficiency or long-term systemic immunosuppressive therapy (such as glucocorticoids ≥ 20 mg/d, More than 4 weeks);
  • Merge with other serious systemic diseases (such as advanced heart failure, end-stage renal disease), affecting study compliance or Survival expectation; ⑥ Pregnant or lactating women; ⑦ Refusing to sign the informed consent form or deemed unsuitable by the researcher to participate in the study.

Treatment and study plan

No intervention; observational biospecimen collection only

Other

No intervention; observational biospecimen collection only

Primary outcomes

  1. Clarify the relationship between airway mucus embolism and secondary pulmonary fibrosis in COPD patients

    Time frame: At the time of surgery and within 6 months after sample collection for laboratory analysis

    By comparing the distal lung tissue of patients undergoing COPD and non COPD lung cancer surgery, a systematic evaluation was conducted to determine the difference between airway mucus thrombus load and the degree of lung tissue fibrosis, and to answer whether airway mucus thrombus is an important pathological factor promoting secondary pulmonary fibrosis in COPD.

Secondary outcomes

  1. The correlation between mucus plugs and clinical features

    Time frame: At the time of surgery and within 6 months after sample collection for laboratory analysis

    Explore the relationship between mucus clot burden and clinical characteristics (such as smoking history, lung function, hypoxic status) and pathological indicators of patients.

    The association between mucus plugs and fibrosis molecular markers:

    Detect and compare epithelial mesenchymal transition (EMT) related molecules (E-cadherin, Vimentin), fibrosis markers (α - SMA, COL1A1), inflammatory markers, etc., to clarify the association between mucosal thrombus load and molecular level fibrosis response.

    Possible functions of Piezo1 channel:

    Preliminary exploration of the correlation between mucus clot load and Piezo1 expression and activity, providing clinical pathological evidence for revealing the role of mechanical pathways in mucus induced fibrosis.

Study contacts

Contact information is provided by the study sponsor or research team.

shengyu hao

CONTACT

[email protected]

18359181031

Sponsors and collaborators

Lead sponsor

Ming Zhong

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 19, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.